Hyderabad, June 2nd, 2025: Sigachi Industries Ltd.
(Sigachi), India’s largest manufacturer of microcrystalline cellulose (MCC),
has demonstrated robust financial performance in FY25 while setting the stage
for aggressive future growth. With a strong EBITDA growth of 46.21% YoY
to ₹1,120 million and a revenue surge of 25.42% to ₹5,003
million, Sigachi is positioning itself for a 25% CAGR through FY28,
driven by capacity expansions, market diversification, and API development.
Commenting on the company’s performance in FY25 and its projected
trajectory, Mr. Amit Raj Sinha, MD & CEO, Sigachi Industries stated: "FY25
has been a transformative year for Sigachi, marked by robust financial outcomes
and strategic expansions across excipients and APIs. With our Hyderabad API
R&D centre going live in Q1 FY26, regulatory approvals flowing in, and
global market penetration deepening, we are positioned for sustainable
high-margin growth. Our 36-year legacy and diversified portfolio give us an
unmatched advantage to scale operations globally while safeguarding
profitability."
Sigachi has created a strategic growth roadmap through to FY 2028
revolving around:
- API Expansion: With
the integration of Trimax Biosciences, the company is scaling its advanced
intermediate and API portfolio. Plans include filing six
additional European CEP dossiers, expanding regulatory approvals,
and ramping up capacity utilisation.
- Market
Diversification: Sigachi is expanding its footprint beyond India,
the U.S., and Europe by aggressively entering Latin America,
Southeast Asia, and the Middle East through new distribution
partnerships and turnkey O&M contracts.
- Excipient Capacity
Growth: Newly commissioned MCC in Jhagadia and Dahej and
CCS project expansions will unlock an additional 8,800 MTPA,
fuelling year-over-year revenue gains of 20%-30% in
excipients. Additionally, new product launches in Pharma Coatings are
expected to be the new growth drivers over the next two years
- Operational
Efficiencies: Digital analytics, lean processing, and energy
efficiency initiatives are expected to trim operating costs by
100-150 basis points annually, preserving EBITDA margins while
mitigating raw-material volatility.
- O&M Services
Expansion: The company is scaling its outsourced
plant-management contracts, which already contribute 10% of
revenues, with a particular focus on Middle East expansion.
Sigachi offers over 82 high-purity excipients—ranging from various
grades of MCC to advanced co-processed blends, and Pharma Coatings, addressing
Pharmaceutical, Nutraceutical, and Specialty chemical needs. The company enjoys
fruitful and long-lasting commercial relationships with over 500 customers in
more than 65 countries. With a clear roadmap and strong execution
capabilities, the company remains committed to delivering sustained financial
performance and market leadership in the years ahead.
About Sigachi Industries Ltd
Founded in 1989, Sigachi Industries Limited is a global player in the
pharmaceutical industry dedicated to pioneering advancements in Active
Pharmaceutical Ingredients (APIs), Intermediates, Excipients, vitamin-mineral
blends, and Operations and Management (O&M) services. The company's diverse
product portfolio is manufactured in 5 multilocational facilities, viz.
Telangana, Gujarat, and Karnataka. Aligned with its ethos of customer
centricity, Sigachi established subsidiaries in UAE and USA to be closer to its
clients and improve responsiveness. With a strong focus on innovation, quality,
and regulatory compliance, we leverage cutting-edge technology and global
expertise to develop high-value pharma, food and nutrition solutions that
enhance healthcare outcomes. Committed to excellence, we continuously invest in
Research and Development, ensuring the highest standards of quality and safety.
With 36 years of industry experience, Sigachi is a trusted partner for
pharmaceutical and nutraceutical companies spread across 65+ countries. Sigachi
collaborates with healthcare partners, regulatory bodies, and global
stakeholders to expand access to reliable, high-quality pharmaceutical
ingredients. Sigachi ranks among the world’s largest and most reputed suppliers
for microcrystalline cellulose (MCC).
Mr. Chaitanya Rapol
Senior Manager – Marketing, Branding and Communications
Sigachi Industries Limited
Email: chaitanya.rapol@sigachi.com
Forward-Looking Statements
This document contains forward-looking statements related to Sigachi
Industries’ future growth prospects, business strategy, operational plans, and
financial performance. These statements are based on current expectations and
assumptions and are subject to risks and uncertainties that could cause actual
results to differ materially. Factors such as regulatory changes, market
conditions, supply chain dynamics, and global economic shifts may impact
outcomes. Sigachi disclaims any obligation to update these statements, except
as required by applicable law.